martes, 3 de enero de 2017

FDA: Trump apuesta por Jim O’Neill (Pro-Cannabis)


President-elect Trump's cabinet appointments are generating a great deal of attention and controversy. After eight years of Democrat rule, it would be foolish to expect otherwise. 

One appointment, though, will have a profound impact on your health… and the health of your loved ones.

Ver:
Trump Team Said to Consider Thiel Associate O’Neill for FDA


The “progressive approval” process for drugs 

The first potential FDA chief appointee leaked by the Trump transition team is Jim O’Neill. Managing director of Peter Thiel’s Mithril Capital, O’Neill has publicly supported proposals to do away with the FDA’s requirement for phase 2 and 3 trials. Instead, he favors “progressive approval” of drugs and other medical technologies. 

Ver:
Glimmer Of Hope: Will Trump Select Pro-Cannabis Head Of FDA? 

O’Neill would not be the first FDA head to favor progressive drug approval. Andrew von Eschenbach developed this system when he served as FDA chief. But during his tenure, Eschenbach was not able to put such a far-reaching reform into practice in the US. (Más)

Ver: 
El efecto que puede tener la legalización de la marihuana en la economía

Todo sobre cannabis medicinal en PHARMACOSERÍAS
Publicar un comentario en la entrada